Clinical Trial

Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

Study acronym: HASHTAG
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-15
Trial Details
NCT Number NCT07523633
Lead Sponsor Anders Fink-Jensen, MD, DMSci
Conditions Cannabis Use Disorder, Cannabis Use Disorders, Cannabis Abuse, Cannabis Dependence, Cannabis Addiction
Enrollment 100 participants
Start Date 2026-04-30
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-14